# MBLVC

> MBLVC is a VC fund in Nagoya backing Medical, Health Care and Biotechnology. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Nagoya, Japan
- Total investments: 4
- Last investment: Jul 2020
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.mblvc.co.jp

MBLVC is a VC fund in Nagoya focused on Medical and Health Care. MBL Venture Capital Co. Ltd. is the investment arm of Medical & Biological Laboratories Co., Ltd. The firm primarily invests in seed, start-up, early, middle to later stage venture companies, including university and research institute-based ventures. It prefers to invest mainly in biotechnology, life science, drug discovery and regenerativemedicine sectors in conjunction with IT applications, some of which are bio-informatics, medical diagnostics and devices, and medical services among others. The firm typically invests in Japan and companies overseas. It prefers to have majority stakes in its portfolio companies. MBL Venture Capital Co., Ltd. was established on January 12, 2000 and is headquartered in Nagoya, Japan with an additional office in Tokyo, Japan.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 50% |
| Health Care | 2 | 50% |
| Biotechnology | 2 | 50% |
| Energy | 1 | 25% |
| mHealth | 1 | 25% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 2 | 50% |
| Seed | 1 | 25% |
| Series D | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| J-Pharma | J-Pharma’s mission is to help mankind by creating and developing novel pharmaceuticals based upon a human-genomic approach; an approach where people with specific diseases are treated with novel and selective agents. J-Pharma’s intellectual property (IP) embraces the notion that cell membrane transporters are tightly associated to many diseases. Inaddition to drug molecules that target specific transporters, J-Pharma has discovered several important drug transporters within the human body that may be used to evaluate and optimize pharmacokinetics of new drug candidates. We believe that J-Pharma’s pipelines will lead to new agents and processes (i.e. diagnostic methods) and will increase the quality of life for an ageing population in industrialized countries. J-Pharma’s overall goal is to contribute globally to the maintenance of human health and improve human welfare through the creation of new drugs. | $16.7M | Series D | Jul 30, 2020 | http://j-pharma.com/index_e.html |
| Himuka AM Pharma | Himuka AM Pharmais a pharmaceutical company. | $49.6M | Seed | Mar 30, 2018 | http://www.himuka-am.com/public/indexj.html |
| KinoPharma | They are engaged in close research and development based on joint research contracts with universities, and they aim to develop clinical drugs with few side effects by utilizing know-how of phosphoenzyme inhibitor research. In addition, they are working on the development of therapeutic agents for intractable diseases such as viral diseases andneurodegenerative diseases, which target kinases. | $35.4M |  | Dec 28, 2016 | https://www.kinopharma.com/ |
| BrightPath Biotherapeutics | BrightPath Biotherapeutics is a stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company develops products based on peptide vaccine technology that stimulates a potent immune response to tumor-associated antigens. | $170.1M |  | Aug 29, 2014 | https://www.brightpathbio.com/ |

4 of 4 investments shown.

## Co-investors
- [Nippon Venture Capital](https://shizune.co/investors/profile/nippon-venture-capital) — VC Fund, 3 deals together
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund, 2 deals together
- [Sansei Capital Investment](https://shizune.co/investors/profile/sansei-capital-investment) — VC Fund, 2 deals together
- [Axil Capital](https://shizune.co/investors/profile/axil-capital) — VC Fund, 1 deal together
- [Fidea Capital](https://shizune.co/investors/profile/fidea-capital) — VC Fund, 1 deal together
- [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund
- [Mizuho Capital](https://shizune.co/investors/profile/mizuho-capital) — VC Fund

## Featured in investor lists
- [Medical Device Investors in Japan](https://shizune.co/investors/medical-device-investors-japan)
- [Medical Device VC Funds in Japan](https://shizune.co/investors/medical-device-vc-funds-japan)

## FAQ

### What does MBLVC invest in?

MBLVC invests primarily in Medical, Health Care and Biotechnology startups, most often at Funding Round and Seed stage. Most of the 4 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did MBLVC last invest?

The most recent investment recorded for MBLVC closed in Jul 2020. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co